Epigral Plans ₹600 Crore Dahej Expansion; Shares Fall 0.23% 

Mumbai July, 27: Epigral Limited plans to invest an estimated ₹600 crore to establish a new manufacturing facility at Dahej, Gujarat, expanding its product portfolio through additional epoxy resin and formulations capacity and a new multi-purpose plant. 

The company disclosed the capital expenditure following its board meeting, as per a regulatory filing under Regulation 30 of the SEBI Listing Regulations. 

The proposed facility will add 1,25,000 tonnes per annum (TPA) of capacity for epoxy resin and formulations. Epigral will also establish a Multi-Purpose Plant (MPP) at the same existing manufacturing location in Dahej.

Both projects are targeted for capacity addition by the second half of FY2028, according to the filing. Epigral said the ₹600 crore estimated investment will be financed through a mix of debt and internal accruals. 

The company cited expansion of its product portfolio and meeting growing demand as the rationale for the capital expenditure. 

Stock Market Snapshot 

The Epigral share price ended at ₹1,160 on July 27, 2026, down ₹2.70, or 0.23%, according to the market data shown. 

The stock saw considerable movement during the session. It traded above ₹1,200 around early afternoon before dropping sharply around 2 PM, briefly moving close to ₹1,115. It subsequently recovered a substantial portion of that decline before the close. 

The ₹600 crore expansion announcement therefore came on a session in which the stock finished only marginally lower despite a much wider trading range during the day.

Epigral Expands Manufacturing Footprint At Dahej 

Epigral operates in the chemicals sector, with its manufacturing operations at Dahej forming an important part of its production base. 

The latest investment will broaden that footprint rather than establish operations at an entirely new location. The company specifically identified epoxy resin and formulations alongside the Multi-Purpose Plant as the products and facilities covered by the expansion programme. 

The planned 1,25,000 TPA epoxy resin and formulations capacity is particularly significant because the regulatory disclosure lists no existing capacity against this project, indicating that the proposed expenditure represents a fresh capacity addition under the disclosed programme. 

Funding through both internal accruals and debt also means the company intends to use a blended financing structure as the project progresses towards its H2 FY2028 timeline. 

Conclusion 

Epigral’s board-backed expansion sets out a ₹600 crore capital expenditure programme at Dahej, with 1,25,000 TPA of proposed epoxy resin and formulations capacity and a new Multi-Purpose Plant. 

Both components are scheduled to be added by H2 FY2028. The company expects the investment to expand its product portfolio and address growing demand, while Epigral shares closed 0.23% lower at ₹1,160 on July 27, 2026.  

Source: 

• https://www.nseindia.com/get-quote/equity/EPIGRAL/Epigral-Limited 
• https://nsearchives.nseindia.com/corporate/MFL_27072026140512_AnnouncementExpansion.pdf